MRUS News and Press, Merus N.V. From 12/25/22

Summary MRUS has traded with wide-reaching volatility over the course of the past 2 years. A series of setbacks on its pipeline conversions has seen a number of rapid selloffs, each resulting in tremendous drawdown. The latest headwind sprouts from the FDA requesting more enrollment...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundber...

Merus N.V. ( NASDAQ: MRUS ) shed ~30% intraday on Thursday after the Dutch biotech said with its Q3 2022 financials that the FDA recommended additional patient enrollment to generate data to support a potential marketing application for bispecific antibody Zenocutuzumab....

Merus press release ( NASDAQ: MRUS ): Q3 GAAP EPS of -$0.53 beats by $0.08 . Revenue of $6.58M (-51.9% Y/Y) misses by $4.42M . As of September 30, 2022, Merus had $372.9 million cash and cash equivalents sufficient to fund company operations beyond 2024. Sh...

The following slide deck was published by Merus N.V. in conjunction with this event. For further details see: Merus (MRUS) Presents at 34th EORTC-NCI-AACR Symposium

Merus N.V. ( NASDAQ: MRUS ) lost ~10% on Wednesday after the Dutch biotech updated initial in-human data for its cancer therapy MCLA-129 from a Phase 1/2 trial involving patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. The readout inclu...

- MCLA-129 observed to be well tolerated with a favorable safety profile - Antitumor activity was observed among heavily pretreated patients, across multiple tumor types and dose levels​ - Initial recommended phase 2 dose 1500 mg every two weeks; expansion cohorts enroll...

– MCLA-129 observed to be well tolerated with preliminary evidence of anti-tumor activity during dose escalation phase – Initial recommended phase two dose set at 1500 mg with dose expansion ongoing – Poster presentation with additional data at ENA available o...

The following slide deck was published by Merus N.V. in conjunction with this event. For further details see: Merus NV (MRUS) Investor Presentation- Slideshow

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecifi...